Literature DB >> 8833686

Prolactin response to fenfluramine and suicide attempt lethality in major depression.

K M Malone, E M Corbitt, S Li, J J Mann.   

Abstract

BACKGROUND: This study employed an alternative method for assessing serotonergic function to further evaluate our finding that cerebrospinal fluid (CSF) 5-hydroxyindole acetic acid (5-HIAA) in depressed suicide attempters with a lifetime history of higher lethality suicide attempts is significantly lower compared to depressed patients who have a history of low lethality suicide attempts.
METHOD: We used dl-fenfluramine (60 mg) as a neuroendocrine probe to examine the serotonin system in 41 in-patients with a DSM-III-R major depressive episode, divided into two groups on the basis of a lifetime history of high or low lethality suicide attempts. Fenfluramine challenge test outcome was defined as the maximum prolactin response in the five hours following fenfluramine.
RESULTS: Patients with a history of a higher lethality suicide attempt had a significantly lower prolactin response to fenfluramine, even when controlling for cortisol, age, sex, weight, comorbid cluster B personality disorder, pharmacokinetic and menstrual cycle effects.
CONCLUSIONS: The data provide further support for the hypothesis that serotonin dysfunction is associated with more lethal suicide attempts, and suggests that higher lethality suicide attempters or failed suicides resemble completed suicides both behaviourally and biochemically.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8833686     DOI: 10.1192/bjp.168.3.324

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  26 in total

1.  5HT-2C receptor polymorphism in suicide victims. Association studies in German and Slavic populations.

Authors:  Jasminka Stefulj; Andreas Büttner; Milovan Kubat; Peter Zill; Melita Balija; Wolfgang Eisenmenger; Brigitta Bondy; Branimir Jernej
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-08       Impact factor: 5.270

2.  Association of 14-3-3 epsilon gene haplotype with completed suicide in Japanese.

Authors:  Masaya Yanagi; Osamu Shirakawa; Noboru Kitamura; Kenji Okamura; Kaoru Sakurai; Naoki Nishiguchi; Takeshi Hashimoto; Hideyuki Nushida; Yasuhiro Ueno; Daiji Kanbe; Meiko Kawamura; Kazuaki Araki; Hiroyuki Nawa; Kiyoshi Maeda
Journal:  J Hum Genet       Date:  2005-04-19       Impact factor: 3.172

Review 3.  Stress, genes and the biology of suicidal behavior.

Authors:  Dianne Currier; J John Mann
Journal:  Psychiatr Clin North Am       Date:  2008-06

Review 4.  G protein-coupled receptors in major psychiatric disorders.

Authors:  Lisa A Catapano; Husseini K Manji
Journal:  Biochim Biophys Acta       Date:  2006-10-03

5.  Adolescent Suicidal Behavior and Substance Use: Developmental Mechanisms.

Authors:  Michael A Dawes; Charles W Mathias; Dawn M Richard; Nathalie Hill-Kapturczak; Donald M Dougherty
Journal:  Subst Abuse       Date:  2008-10-31

Review 6.  The serotonergic system in mood disorders and suicidal behaviour.

Authors:  J John Mann
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

7.  Future suicide attempt and responses to serotonergic challenge.

Authors:  John G Keilp; Maria A Oquendo; Barbara H Stanley; Ainsley K Burke; Thomas B Cooper; Kevin M Malone; J John Mann
Journal:  Neuropsychopharmacology       Date:  2008-03-19       Impact factor: 7.853

Review 8.  Biological basis of suicide and suicidal behavior.

Authors:  Ghanshyam N Pandey
Journal:  Bipolar Disord       Date:  2013-06-15       Impact factor: 6.744

9.  Serotonergic responses in depressed patients with or without a history of alcohol use disorders and healthy controls.

Authors:  Leo Sher; Barbara H Stanley; Thomas B Cooper; Kevin M Malone; J John Mann; Maria A Oquendo
Journal:  Eur Neuropsychopharmacol       Date:  2008-06-30       Impact factor: 4.600

10.  A comparison of d, l-fenfluramine and citalopram challenges in healthy adults.

Authors:  Janine D Flory; Stephen B Manuck; James M Perel; Matthew F Muldoon
Journal:  Psychopharmacology (Berl)       Date:  2004-03-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.